Affimed’s (AFMD) “Overweight” Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Affimed (NASDAQ:AFMD) in a report issued on Monday, Benzinga reports.

AFMD has been the subject of several other research reports. HC Wainwright reissued a buy rating and issued a $10.00 target price on shares of Affimed in a research report on Friday, September 6th. Laidlaw boosted their price objective on Affimed from $15.00 to $25.00 and gave the company a buy rating in a report on Thursday, June 13th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. Based on data from MarketBeat, Affimed presently has a consensus rating of Moderate Buy and an average price target of $32.50.

Affimed Price Performance

Shares of AFMD opened at $3.85 on Monday. The company has a quick ratio of 2.71, a current ratio of 2.71 and a debt-to-equity ratio of 0.13. The business’s 50 day moving average is $4.59 and its two-hundred day moving average is $5.21. Affimed has a 52-week low of $2.23 and a 52-week high of $8.95.

Affimed (NASDAQ:AFMD) last posted its quarterly earnings results on Wednesday, June 12th. The biopharmaceutical company reported ($1.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.73) by $0.35. Affimed had a negative net margin of 2,922.74% and a negative return on equity of 155.30%. The firm had revenue of $0.17 million for the quarter, compared to analysts’ expectations of $1.76 million. As a group, equities research analysts predict that Affimed will post -3.6 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. BNP Paribas Financial Markets grew its position in shares of Affimed by 39.9% during the 4th quarter. BNP Paribas Financial Markets now owns 571,975 shares of the biopharmaceutical company’s stock valued at $357,000 after buying an additional 163,162 shares during the last quarter. Vestal Point Capital LP bought a new position in Affimed in the fourth quarter worth about $341,000. Finally, Choreo LLC acquired a new position in Affimed in the second quarter valued at approximately $54,000. 30.82% of the stock is currently owned by institutional investors.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia.